Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA-B-Fab PET in ovarian and breast cancer
NCT02708511Phase 1Terminated
- Start
- Aug 2016
- Primary completion
- Oct 2017
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copper cu 64-dota b-fab in ovarian carcinoma and breast carcinoma. Primary endpoints: Biodistribution of copper Cu 64 DOTA-B-Fab at 24 hours and Dosimetry of copper Cu 64 DOTA-B-Fab. Started Aug 2016; status: terminated.
02
Drugs
copper cu 64-dota b-fab
03
Conditions
ovarian carcinomabreast carcinoma
Beyond the preview
Go deeper on NCT02708511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02708511.